The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 3, 2011, Pages 302-308

  Nguyen, Paul L ^a   Lin, Douglas I ^a   Lei, Junyi ^a   Fiorentino, Michelangelo ^a   Mueller, Elke ^a   Weinstein, Michael H ^a   Pagano, Michele ^a   Loda, Massimo ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarker; Prostate cancer; Recurrence; Skp2

Indexed keywords

KI 67 ANTIGEN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CELL STRAIN LNCAP; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TRANSURETHRAL RESECTION;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; S-PHASE KINASE-ASSOCIATED PROTEINS; TUMOR CELLS, CULTURED;

EID: 79955745145     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.022     Document Type: Article

References (18)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
2. Hershko D.D. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008, 112:1415-1424.
3. Carrano A.C., Eytan E., Hershko A., et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999, 1:193-199.
4. Sutterluty H., Chatelain E., Marti A., et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999, 1:207-214.
5. Tsvetkov L.M., Yeh K.H., Lee S.J., et al. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999, 9:661-664.
6. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
7. Signoretti S., Di Marcotullio L., Richardson A., et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002, 110:633-641.
8. Yang R.M., Naitoh J., Murphy M., et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159:941-945.
9. Ben-Izhak O., Lahav-Baratz S., Meretyk S., et al. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol 2003, 170:241-245.
10. Ghanem M.A., Van der Kwast T.H., Sudaryo M.K., et al. MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. Clin Cancer Res 2004, 10:591-597.
11. Yang G., Ayala G., De Marzo A., et al. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002, 8:3419-3426.
12. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume, and benign hyperplasia. J Urol 1990, 143:747-752.
13. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
14. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol 2009, 181:956-962.
15. Slotky M., Shapira M., Ben-Izhak O., et al. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 2005, 7:R737-R744.
16. Shapira M., Kakiashvili E., Rosenberg T., et al. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res 2006, 8:R46.
17. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433-439.
18. Freedland S.J., deGregorio F., Sacoolidge J.C., et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 2003, 169:1325-1330.